Post by Mirum Pharmaceuticals, Inc.

Mirum and Incyte announced positive pivotal Phase 2 results from the PROGRESS study evaluating an investigational ALK2 inhibitor in adolescents and adults living with fibrodysplasia ossificans progressiva (#FOP). Learn more in our press release: https://bit.ly/4xrTZA3